Published in Vaccine Weekly, November 16th, 2005
Earlier closings of this round were used to complete the company's phase 1 clinical trial for the company's VRX496 gene-based anti-HIV immunotherapy. The remainder of the funds will be used for their phase 2 trial and to continue to advance the development of the company's lentiviral vector platform technology.
The series F offering was VIRxSYS' fifth financing round since the company's founding in 1998. The company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.